Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 02, 2026 09:30 ET | Source: Legend Biotech USA Inc.

Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)

Promising Phase 1 data for LB2501, a potential first‑in‑class CD19/CD20 dual‑targeting in vivo CAR-T therapy, as an off-the-shelf, single-infusion treatment for B‑cell malignanciesAn ORR of 100% (6/6)...
June 01, 2026 10:00 ET | Source: Legend Biotech USA Inc.

Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026

LB2102 demonstrated a manageable safety profile and encouraging clinical activity in solid tumors among heavily pretreated patients Responses observed at higher dose levels of LB2102 with an ORR of...
May 21, 2026 17:00 ET | Source: Legend Biotech USA Inc.

Legend Biotech Announces Presentations at ASCO 2026

Preliminary results from Phase 1 data for LB2102 to reinforce early evidence of activity in solid tumors in a rapid oral presentation New data from the CARTITUDE-4 study to highlight a cytogenetic...
May 12, 2026 07:00 ET | Source: Legend Biotech USA Inc.

Legend Biotech Reports First Quarter 2026 Results and Recent Highlights

CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 62% versus first quarter of 2025 to approximately $597 millionCARVYKTI® now available across 18 global markets, following...
May 04, 2026 08:00 ET | Source: Legend Biotech USA Inc.

Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth

SOMERSET, N.J., May 04, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the engagement with a group of...
April 28, 2026 08:00 ET | Source: Legend Biotech USA Inc.

Legend Biotech to Host Investor Conference Call on First Quarter 2026 Results

SOMERSET, N.J., April 28, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am...
March 10, 2026 07:00 ET | Source: Legend Biotech USA Inc.

Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights

CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $555 million and $1.9 billion for the fourth quarter and full year 2025, respectivelySurpassed milestone of more than...
February 24, 2026 08:00 ET | Source: Legend Biotech USA Inc.

Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2025 Results

SOMERSET, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET...
January 21, 2026 08:00 ET | Source: Legend Biotech USA Inc.

Legend Biotech to Present CARVYKTI® Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use

Six poster presentations highlight CARVYKTI® efficacy, safety, and real-world outcomes across CARTITUDE trials and analyses, reflecting a maturing and expanding body of evidence SOMERSET, N.J., Jan. ...
January 12, 2026 08:00 ET | Source: Legend Biotech USA Inc.

Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference

Exceeded 10,000 patients treated to date with CARVYKTI® (ciltacabtagene autoleucel; cilta-cel)Increased CARVYKTI® manufacturing capacity with the physical expansion of the Raritan facility, now the...